CollPlant Biotechnologies (CLGN) Projected to Release Quarterly Earnings on Thursday

CollPlant Biotechnologies (NASDAQ:CLGN) will likely be posting its Q2 2026 results before the market opens on Thursday, August 20th. Analysts expect CollPlant Biotechnologies to post earnings of ($0.2448) per share and revenue of $0.48 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 26, 2026 at 12:30 PM ET.

CollPlant Biotechnologies (NASDAQ:CLGN) last released its quarterly earnings results on Saturday, May 30th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. CollPlant Biotechnologies had a negative return on equity of 218.81% and a negative net margin of 683.68%.The business had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.46 million.

CollPlant Biotechnologies Trading Down 1.7%

Shares of NASDAQ:CLGN opened at $0.31 on Wednesday. The stock’s fifty day simple moving average is $0.33 and its two-hundred day simple moving average is $0.49. CollPlant Biotechnologies has a 1-year low of $0.27 and a 1-year high of $3.18. The stock has a market cap of $4.54 million, a PE ratio of -0.22 and a beta of 1.67.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of CollPlant Biotechnologies from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, June 8th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, CollPlant Biotechnologies currently has an average rating of “Hold” and an average target price of $11.50.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a regenerative medicine company that develops and commercializes recombinant human collagen (rhCollagen) and 3D bioprinting technologies for medical and aesthetic applications. The company’s proprietary plant-based rhCollagen is produced using genetically engineered tobacco plants to provide a scalable, animal-free source of human collagen that meets regulatory standards.

CollPlant’s product portfolio includes Vergenix™ wound care matrices and dermal fillers for aesthetic and reconstructive purposes, as well as a range of bioinks designed for 3D bioprinting of soft and hard tissues.